Evidence map›Paper›PMID 37456760›Full record

ArticleFrontiers in pharmacology2023

Novel structured ADAM17 small-molecule inhibitor represses ADAM17/Notch pathway activation and the NSCLC cells' resistance to anti-tumour drugs.

Meng Chi, Yamin Jie, Ying Li, Duo Wang, Man Li, Dan Li, Mingyan E, Yongwu Li, Na Liu, Anxin Gu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Meng ChiDepartment of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Yamin JieDepartment of Radiation Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Ying LiHeilongjiang Provincial Key Laboratory of Hard Tissue Development and Regeneration, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Duo WangDepartment of Neurology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Man LiDepartment of Endoscopy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Dan LiDepartment of Radiation Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Mingyan EDepartment of Radiation Oncology, Harbin Medical University Cancer Hospital, Heilongjiang, China.
Yongwu LiDepartment of Nuclear Medicine, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Na LiuDepartment of Nuclear Medicine, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Anxin GuDepartment of Radiation Oncology, Harbin Medical University Cancer Hospital, Heilongjiang, China.
Guanghua RongDepartment of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Harbin Medical University · CNChinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antitumour drugslung adenocarcinomalung squamous cell carcinomanon-small-cell lung cancersmall-molecule inhibitor

Identifiers

PMID37456760
PMCPMC10338884
OpenAlexW4382727284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.